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Alkylating agents have long played a central role in the adjuvant therapy of glioblas-
toma (GBM). More recently, inclusion of temozolomide (TMZ), an orally administered
methylating agent with low systemic toxicity, during and after radiotherapy has markedly
improved survival. Extensive in vitro and in vivo evidence has shown that TMZ-induced
O6-methylguanine (O6-meG) mediates GBM cell killing. Moreover, low or absent expres-
sion of O6-methylguanine-DNA methyltransferase (MGMT), the sole human repair protein
that removes O6-meG from DNA, is frequently associated with longer survival in GBMs
treated with TMZ, promoting interest in developing inhibitors of MGMT to counter resis-
tance. However, the clinical efﬁcacy of TMZ is unlikely to be due solely to O6-meG, as
the agent produces approximately a dozen additional DNA adducts, including cytotoxic
N3-methyladenine (3-meA) and abasic sites. Repair of 3-meA and abasic sites, both of
which are produced in greater abundance than O6-meG, is mediated by the base excision
repair (BER) pathway, and occurs independently of removal of O6-meG.These observations
indicate that BER activities are also potential targets for strategies to potentiateTMZ cyto-
toxicity. Here we review the evidence that 3-meA and abasic sites mediate killing of GBM
cells.We also present in vitro and in vivo evidence that alkyladenine-DNA glycosylase, the
sole repair activity that excises 3-meA from DNA, and Ape1, the major human abasic site
endonuclease, mediate TMZ resistance in GBMs and represent potential anti-resistance
targets.
Keywords: alkyladenine-DNA glycosylase,Ape1, apurinic endonuclease, DNA repair, treatment outcome, predictive
marker
INTRODUCTION
Methylating and chloroethylating agents have long been used in
the adjuvant therapy of glioblastoma (GBM) and other malig-
nant gliomas (Chamberlain, 2011). Inclusion of the methylator
temozolomide (TMZ) during radiotherapy (RT) and continued
administration of TMZ as a single agent afterward produces
signiﬁcant improvement in survival, marking a milestone in
neuro-oncology (Stupp et al., 2009). Better outcome with concur-
rent TMZ-RT is associated with methylation of CpG dinucleotides
in the promoter of the gene for O6-methylguanine-DNA methyl-
transferase (MGMT), indicative of silencing of expression of the
sole human activity that removes TMZ-induced radiosensitizing
and cytotoxic O6-methylguanine (O6-meG) adducts from DNA
(Hegi et al., 2005; Stupp et al., 2009). This observation has raised
expectations that MGMT promoter methylation status can be
used to direct treatment of individual tumors (e.g., Weller et al.,
2012). However, promoter methylation status does not accurately
predict outcome in all GBM, indicating that additional intrinsic
factors inﬂuence survival (Silber et al., 2012). Importantly, TMZ
produces a host of potentially cytotoxic DNA adducts in addi-
tion to O6-meG that are not repaired by MGMT (Shrivastav et al.,
2010; Fu et al., 2012). Here we summarize evidence that excision
of N3-methyladenine (3-meA) by alkyladenine-DNA glycosylase
(AAG), and repair of abasic sites by the apurinic/apyrimidinic
endonuclease (Ap endo) activity of Ape1, also mediate GBM
resistance to TMZ and other alkylators.
TMZ PRODUCES A VARIETY OF CYTOTOXIC DNA BASE
ADDUCTS
Temozolomide and other clinically relevant methylating agents
(e.g., procarbazine, streptozotocin) are SN1-type alkylators that
undergo spontaneous hydrolysis at physiological pH to form a
methyldiazonium ion that reacts at nucleophilic ring nitrogens
and extra-cyclic oxygens on purine and pyrimidines (Fu et al.,
2012). In double-stranded DNA, reaction occurs predominantly
at the N7 of guanine, N3 of adenine and O6 of guanine, account-
ing for approximately 70, 10, and 7% of base adducts, respectively
(Table 1). The next two most frequent sites of adduction, N1 of
adenine and N3 of cytosine (Table 1), are unusual in that they
occur predominantly in single-stranded DNA such as would be
found at DNA replication forks and at sites of gene transcription
in vivo (Sedgwick et al., 2007). Methylation has also been detected
at N1 and N3 of guanine, N7 of adenine, N3 of thymine, O4 of
thymine, and O2 of cytosine, but these lesions comprise less than
5% of total base adducts in double-stranded DNA (Wyatt and
Pittman, 2006). With the exception of the N3 position of adenine,
clinically utilized, nitrosourea-derived chloroethylating agents
(e.g., carmustine, lomustine) react at many of the same sites as
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7-meG 70 Innocuous – AAG
3-meA 10 Cytotoxic Polymerase contact AAG
O6-meG 5–7 Cytotoxic Base-pairing MGMT
1-meA 2.8b Cytotoxic Polymerase contact ABH2/ABH3
3-meC 2.3b Cytotoxic Polymerase contact ABH2/ABH3
Minor adducts
7-meA 1.7 Innocuous – AAG
3-meG 0.8 Cytotoxic Polymerase contact AAG
O4-meT 0.4 Cytotoxic Base-pairing MGMT
1-meG 1b Cytotoxic Polymerase contact ABH2/ABH3;
AAGc
3-meT 1b Cytotoxic Polymerase contact ABH2/ABH3
O2-meC 1 Cytotoxic Base-pairing ?
O2-meT 1 Cytotoxic Polymerase contact ?
aCompiled from Beranek (1990), Drabløs et al. (2004), Wyatt and Pittman (2006),
Lee et al. (2009), and Shrivastav et al. (2010).
b In single-stranded DNA.
c In double-stranded DNA.
TMZ, forming a number of potentially lethal monoadducts, exo-
cyclic ethano adducts, and inter-strand cross-links, including the
cytosine-guanine cross-link produced by O6-chloroethylguanine
(Ludlum, 1997).
As shown in Table 1, most methyl base adducts are implicated
in promoting lethality, and cytotoxicity is strongly associated with
blockedor interruptedDNAreplication (Fu et al., 2012). Cytotoxic
methyl adducts occur at positions on bases that are contacted by
DNA polymerases (e.g., N3 of adenine) or are involved inWatson–
Crick base-pairing (e.g., O6 of guanine). Lesions such as 3-meA
prevent the contacts with critical amino acid residues in replica-
tive DNA polymerases that are obligatory for synthesis (Plosky
et al., 2008; Sidorova, 2008; Myers et al., 2009). Blocked replication
forks are unstable and produce potently cytotoxic double-strand
breaks (DSBs) upon collapse. The commonly known lesion that
disrupts base-pairing, O6-meG, does not block replication fork
progression directly but allows incorporation of either cytosine or
thymine, neither of which can correctly base-pair with the adduct
(Roos and Kaina, 2012). The resulting mis-pair is recognized and
the inserted base excised by the mismatch repair pathway, pro-
ducing a long single-strand gap in newly synthesized DNA. Repair
DNA synthesis to ﬁll the gap produces another mis-pair, eliciting
a futile cycle of excision and resynthesis, and the resulting single-
strand gap produces a DSB during the next S-phase (Quiros et al.,
2010). The single-stranded regions that result from replication
blockage or the action of mismatch repair may also be responsible
for the radiosensitizing effect of TMZ, since these sites are read-
ily converted into DSBs by free radical-mediated strand cleavage
(Bobola et al., 2010).
The most abundant TMZ base lesion, N7-methylguanine (7-
meG), is innocuous, probably reﬂecting its position in the major
groove of DNA that removes it from the path of DNA replication.
However, methylation at the N7 position of guanine as well as at
other sites in purines (e.g., N7 of adenine, N3 of guanine) can
greatly accelerate the rate of hydrolysis of the glycosylic linkage
that binds bases to deoxyribose (Loeb and Preston, 1986; Shri-
vastav et al., 2010). The resulting abasic sites are strong blocks to
replication (Wilson and Barsky, 2001), and because of the prepon-
derance of N-methyl adducts produced by methylating agents,
are likely the most abundant potentially lethal lesion produced
by TMZ.
REPAIR OF METHYL BASE ADDUCTS IN DNA
A number of DNA repair pathways promote GBM resistance
to TMZ-induced base adducts. The best characterized of these
is MGMT, which functions solely to restore O6-meG to gua-
nine by transferring the methyl group to an internal cysteine
residue (Silber et al., 2012). However, the most abundant TMZ-
induced adducts, 7-meG, 3-meA, and abasic sites are excised from
DNA by the short patch base excision repair (BER) pathway, a
carefully coordinated, multi-step process that replaces a single
nucleotide containing a damaged base (Fu et al., 2012). BER is
an evolutionarily conserved repair pathway that primarily func-
tions against endogenously generated DNA damage caused by
the intrinsic instability of DNA and by oxidative metabolism
(Robertson et al., 2009). The amount of such damage in normal
cells is substantial with as many as 50,000 BER lesions formed
daily. These spontaneously generated DNA adducts, includ-
ing oxidized and alkylated bases, abasic sites, and single-strand
breaks (SSBs), are identical to those generated by therapeu-
tic ionizing radiation and many clinically utilized alkylating
agents.
The BER of 3-meA and 7-meG is initiated by adduct recogni-
tion by AAG (also methylpurine-DNA glycosylase or alkylpurine-
DNA-N-glycosylase) followed by cleavage of the glycosylic linkage
between the damaged base and deoxyribose, producing an abasic
site in DNA (Figure 1). AAG remains bound to the abasic site
and recruits Ape1, the major human Ap endo (Abbotts and Mad-
husudan, 2010), which cleaves the DNA phosphodiester backbone
to form a SSB with 3′-OH and 5′ deoxyribose phosphate (dRP)
termini. Ape1 is then replaced by DNA polymerase β, a repair
polymerase possessing a 5′ lyase activity that excises the 5′ dRP
to yield a single nucleotide gap. The gap is ﬁlled by DNA poly-
merase β, leaving a strand break that is immediately sealed byDNA
ligase III. The tightly coordinated mechanism of BER, necessary
prevent accumulation of potentially lethal repair intermediates
(i.e., abasic sites, 5′ dRPs, SSBs), is mediated by the protein
XRCC1 which serves as a scaffold to foster the sequential action
of each repair enzyme. In addition, poly(ADP-ribose) polymerase
(PARP) facilitates repair by binding to SSBs and synthesizing long
poly(ADP-ribose) chains that recruit XRCC1, DNA polymerase
β, and DNA ligase to the site of repair. The coordinated action
of BER components is essential for methylator resistance, as evi-
denced by the increased cytotoxicity that accompanies unbalanced
repair produced either by suppressed or enhanced expression of
key elements (Fu et al., 2012).
Frontiers in Oncology | Radiation Oncology November 2012 | Volume 2 | Article 176 | 2
“fonc-02-00176” — 2012/11/30 — 11:16 — page 3 — #3
Bobola et al. BER mediates GBM temozolomide resistance
FIGURE 1 | Removal of 3-meA by base excision repair (BER).
TMZ-induced 3-meA in DNA is recognized by AGG that excises the
methylated base by cleaving the glycosylic linkage between the adducted
base and deoxyribose. AAG remains bound to the resulting abasic site
(ABS) until displaced by Ape1. The apurinic endonuclease activity of Ape1
incises the DNA phosphodiester backbone immediately 5′ to the abasic
site, producing a single-strand break (red square) containing a
5′-deoxyribose phosphate (5′-dRP) terminus. Ape1 is replaced by DNA
polymerase β (Pol β) that removes the 5′-dRP via an intrinsic lyase activity
to produce a single-nucleotide gap (red line). Using the opposite DNA
strand as a template, Pol β then inserts a complementary nucleotide
leaving a single-strand break (red square) that is subsequently sealed by
DNA ligase. This process is closely coordinated to insure that the
potentially lethal abasic sites, and single strand breaks and gaps do not
persist. XRCC1 and PARP (not shown) facilitate repair by coordinating
protein binding at damage sites. BER is also essential for repair of abasic
sites that arise from spontaneous or methylation-enhanced base loss and
single-strand breaks produced by ionizing radiation. Some radiation-induced
strand breaks contain fragmented or 5′-oxidized deoxyribose moieties that
cannot be excised by the lyase activity of Pol β. In this circumstance an
alternative BER pathway employs FEN1 endonuclease to excise a two to
eight nucleotide long single-strand containing the damage, and the
resulting gap is ﬁlled by DNA polymerase δ or ε and sealed by DNA ligase
(Robertson et al., 2009).
Short patch BER is not the sole mechanism in human cells
that promotes methylator resistance by removing N-methylated
bases from DNA. 1-meA and 3-meC are demethylated in situ by
the DNA dioxygenases ABH2 and ABH3 (Sedgwick et al., 2007).
Other mechanisms promote tolerance of unrepaired lesions, e.g.,
translesion synthesis by Y family DNA polymerases (Plosky et al.,
2008; Monti et al., 2010), replication restart at stalled forks
(Blank et al., 2004), and rejoining of DSBs arising at sites of
blockedDNA replication by homologous recombination and non-
homologous end joining (Nikolova et al., 2010; Quiros et al.,
2011). Full characterization of the contribution of these addi-
tional mechanisms to TMZ resistance in human gliomas awaits
further study.
AAG PROMOTES RESISTANCE TO TMZ
Bacteria, yeast, and mammalian cells unable to excise 3-meA are
hypersensitive to laboratory and clinically utilized methylating
agents (Fronza and Gold, 2004; Wyatt and Pittman, 2006). Evi-
dence that repair of 3-meA mediates alkylator resistance in human
cancer cells has come from experiments in which AAG expression
was suppressed and from studies using unique, sequence-speciﬁc
alkylators that produce 3-meA as their sole cytotoxic lesion
(Fronza and Gold, 2004). Below, we discuss the evidence that
repair of 3-meA by AAG contributes to TMZ resistance in human
GBM cells and tumors.
AAG SUBSTRATE SPECIFICITY AND PHYSIOLOGICAL ROLE
Alkyladenine-DNA glycosylase is one of 11 human DNA gly-
cosylases characterized to date, and appears to be the primary
activity that excises 3-meA and 7-meG from DNA (Fu et al.,
2012). Unlike most DNA glycosylases, AAG has broad substrate
speciﬁcity that includes oxidized and alkylated bases (Wyatt and
Pittman, 2006). Hypoxanthine, a mutagenic deamination prod-
uct of adenine, is the preferred substrate and is excised at least
1,000-fold more efﬁciently than alkyl adducts (O’Brien and Ellen-
berger, 2004; Lee et al., 2009). Of the N-methylpurines, 3-meA
is excised at a greater rate than 7-meG, and there is no evi-
dence suggesting that AAG excises other methylated purines, or
methylated pyrimidines in vivo. The catalytic activity of AAG
against N-methylpurines is very modest in that, compared to
spontaneous depurination, it reduces the half-lives for 3-meA
and 7-meG in DNA only about a 1,000-fold (i.e., from hours
to minutes), far less than the >1020 rate enhancements yielded
by most enzymes (O’Brien and Ellenberger, 2004). Excision of 7-
meG, an innocuous adduct, by AAG to yield a cytotoxic abasic
site could be a consequence of the broad substrate speciﬁcity of
the enzyme; however, such excision may confer a selective advan-
tage by preventing spontaneous depurination that would yield an
unprotected abasic site. Of note, other AAG substrates include
the DNA blocking adducts bases 1,N6-ethanoadenine and 1,N6-
ethenoadenine produced by 1,3-bis(2-chloroethyl)-1-nitrosourea
(BCNU) and cyclophosphamide, respectively, two agents used
to treat recurrent GBMs (e.g., Chamberlain and Tsao-Wei, 2004;
Stupp et al., 2007).
Mice homozygous null for Aag are viable, develop normally
and do not display enhanced rates of spontaneous carcinogene-
sis. However, Aag−/− animals and primary embryonic ﬁbroblasts
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do show increased sensitivity to methylating agents (Engelward
et al., 1998). In accord, suppressing AAG expression with siRNA
produced hypersensitivity to TMZ and other alkylators in HeLa
and ovarian carcinoma cells (Paik et al., 2005). Yet, the impor-
tance of AAG in countering methylator genotoxicity in normal
cells is not unambiguous, as evidenced by results showing that
loss of activity is not necessarily accompanied by greater methyla-
tor sensitivity in some cell types (Wyatt and Pittman, 2006). For
example, Aag−/− mouse myeloid bone marrow cells are more
resistant to methylator-induced killing than wild-type cells, sug-
gesting that excision of methyl adducts by AAG might promote
killing. Notably, over-expression of AAG in rodent and human
cancer cells increases sensitivity to methylators, including TMZ,
that has been attributed to an imbalance in BER resulting in
accumulation of cytotoxic abasic sites (e.g., Rinne et al., 2005;
Tang et al., 2011). As discussed below, greater TMZ resistance
accompanies high levels of AAG expression in human GBM tissue,
indicating that unbalanced BER does not commonly accompany
glial tumorigenesis.
AAG PROMOTES TMZ RESISTANCE IN HUMAN GBM AND
GLIOMA CELLS
Early work from our laboratory strongly indicated that DNA
adducts in addition to O6-meG cause TMZ cytotoxicity in human
GBM cell lines, and that MGMT is not the only, or even the prin-
cipal, agent of TMZ resistance (Bobola et al., 1996). We addressed
this hypothesis directly by examining the sensitivity of a panel
of 10 human glioma cell lines to methyl-lexitropsin (Me-Lex),
a novel, sequence-speciﬁc alkylating agent that produces 3-meA
as the predominant (i.e., >90%) base adduct (Fronza and Gold,
2004). Suppressing AAG activity with antisense oligonucleotides
(ASO) in MGMT-expressing, MGMT-deﬁcient and MGMT- and
mismatch repair-deﬁcient GBM lines increased Me-Lex sensitiv-
ity assayed by survival of colony-forming ability (Bobola et al.,
2007). Importantly, greater cell killing was accompanied by
reduced content of abasic sites, the product of AAG-mediated
excision of 3-meA. These ﬁnding provide strong evidence that
unrepaired 3-meA is a potentially lethal lesion in human glioma
cells and suggest that 3-meA plays a role in TMZ-induced
cell killing.
Further evidence that TMZ-induced 3-meA contributes to cell
killing was described in recent work examining the TMZ sensitiv-
ity of A172 cells, a human GBM cell line that has no detectable
AAG or MGMT protein by Western blotting (Agnihotri et al.,
2012). In these experiments variant lines were constructed that
either expressed AAG alone, MGMT alone, or both repair activ-
ities. The variant line expressing AAG alone displayed elevated
resistance to TMZ that was accompanied by decreased content of
7-meG, relative to the repair-deﬁcient parental line. Co-expression
of AAG and MGMT resulted in yet greater TMZ resistance, con-
sistent with independent contributions of AAG and MGMT to
resistance. In complementary experiments, Agnihotri et al. (2012)
showed that shRNA-mediated suppression of endogenous AAG
increased sensitivity to TMZ in the GBM cancer stem cell line
GBM6, and tomethylmethanesulfonate (MMS), amethylator that
produces very littleO6-meG, in theGBM lineT98G.More recently,
our laboratory found that ASO-mediated suppression of AAG
activity increased TMZ killing in MGMT-expressing, MGMT-
deﬁcient and MGMT- and mismatch repair-deﬁcient GBM lines
(Bobola et al., in preparation), providing additional evidence that
TMZ-induced 3-meA promotes cytotoxicity in GBM cells. Ele-
vated content of γ-H2AX, a surrogate marker for DSBs (Bonner
et al., 2008), accompanied greater sensitivity to TMZ in ASO-
treated cells, suggesting that unrepaired 3-meA is a precursor of
lethal DSBs.
A role for AAG in TMZ resistance was further supported
by examination of a panel of 19 xenografts established by
intra-cranial implantation of human GBM tissue in nude mice
(Agnihotri et al., 2012). AAG expression was undetectable by
immunohistochemistry (IHC) in 11 of 19 (58%) xenografts, and
absence of AAG was accompanied by signiﬁcantly longer sur-
vival following treatment with TMZ. Comparable results were
observed for survival of nudemice bearing intra-cranial xenografts
derived from the A172 variant lines following treatment with
TMZ, yielding strong evidence that 3-meA and O6-meG con-
tribute independently to TMZ cytotoxicity. Interestingly, TMZ
sensitivity was the same in variants expressing AAG alone or
MGMT alone, suggesting that unrepaired 3-meA and O6-meG
were equally cytotoxic.
A growing body of evidence indicates that TMZ is a radiosen-
sitizing agent and that this property is partly responsible for the
clinical efﬁcacy of concomitant treatment with TMZ and radi-
ation (Silber et al., 2012). Radiosensitization is most evident in
MGMT-deﬁcient GBM cells leading to the conclusion that fail-
ure to repair O6-meG promotes radiation sensitivity. In addition,
we have reported that ASO-mediated suppression of AAG activ-
ity enhanced radiation killing in MGMT-expressing and MGMT-
and mismatch repair-deﬁcient GBM cells treated with minimally
cytotoxic doses of TMZ (Bobola et al., 2010), indicating that 3-
meA also promotes radiosensitization. Comparable increases in
radiosensitivity were obtained when cells were exposed to Me-
Lex, a methylator that produces almost exclusively 3-meA (Bobola
et al., in preparation). In accord with these ﬁndings is the recent
report that nude mice bearingAAG-deﬁcient A172 xenografts sur-
vived signiﬁcantly longer following concurrent treatment with
TMZ and radiation compared to xenografts of AAG-expressing
A172 variants (Agnihotri et al., 2012). These results strongly indi-
cate that 3-meA as well as O6-meG contribute to TMZ-induced
radiosensitization.
AAG IN GLIOMA TISSUE AND ASSOCIATION WITH
TREATMENT RESPONSE
A number of studies have shown that gliomagenesis is accompa-
nied by elevation of AAG expression as demonstrated by greater
AAG mRNA content in gliomas relative to adjacent brain (Kim
et al., 2003; Tang et al., 2011; Liu et al., 2012). IHC analysis of
GBM and other gliomas revealed predominantly nuclear expres-
sion of AAG protein that displayed considerable inter-tumoral
heterogeneity, with 20–30% of specimens having no detectable
protein (Agnihotri et al., 2012; Liu et al., 2012). The analysis by
Agnihotri et al. (2012) revealed that absence of detectable pro-
tein is associated with extensive methylation of promoter CpG
islands, suggesting that AAG expression is epigenetically regulated
in GBMs. Our recent analysis of AAG activity in 80 GBMs revealed
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a greater than a 820-fold range in activity (Bobola et al., in prepa-
ration). Only four tumors (∼6%) lacked detectable activity, likely
reﬂecting the greater sensitivity of biochemical assay compared to
IHC for detection of AAG.
Agnihotri et al. (2012) found that AAG expression, assessed
by IHC, is inversely associated with overall survival in GBMs.
In a sample of 37 GBMs, patients with immunonegative tumors
had signiﬁcantly longer overall survival following concurrent ther-
apy with TMZ and radiation than patients with AAG-expressing
tumors. Examination of AAG protein expression in another set of
27 GBMs displaying MGMT promoter methylation, a marker of
low or absent MGMT expression, revealed that tumors with over-
all survival>1 year were signiﬁcantly more likely to lack detectable
AAG compared to tumors with shorter survival. These data sug-
gest that AAG promotes resistance to TMZ-RT independently
of MGMT. In accord with this conclusion, analysis of a larger
set of tumor samples from the EORTC-NCIC trial (Stupp et al.,
2009) revealed that undetectableAAG correlated with signiﬁcantly
longer overall survival (P = 0.04) inGBMs treatedwith concurrent
TMZ-RT, regardless of MGMT promoter methylation status. That
this relationship reﬂected repair of TMZ-induced DNA damage
was evidenced by lack of an association between AAG expression
and survival in GBMs treated with radiation only.
Our laboratory has recently completed a preliminary exam-
ination of the association of AAG biochemical activity with
progression-free survival (PFS) following alkylator treatment in
60 de novo GBMs that differed in activity by 820-fold. Forty-three
tumors were treated with radiation followed by alkylator-based
chemotherapy, including 23 that received TMZ. The remaining
17 tumors were treated with concurrent TMZ-RT. A dichotomous
Cox proportional hazards regression model with median activity
as the cut point revealed a strong inverse trendbetween activity and
PFS with the risk of progression changing by a factor of 1.64 for
each unit of AAG activity (P = 0.082). Including MGMT activity
as a covariate yielded a signiﬁcant association with a hazard ratio
(HR) = 1.96 (P = 0.033), suggesting that AAG and MGMT inde-
pendently promote alkylator resistance. Comparable trends were
observed when analysis was restricted to the 43 tumors treated
with TMZ (HR = 1.90; P ≤ 0.10) and the 17 treated with con-
current TMZ-RT (HR = 3.42; P ≤ 0.15). The inverse association
was also observed when AAG activity was entered as a continu-
ous variable in a univariate Cox model (HR = 1.002; P ≤ 0.047);
addition of MGMT activity as a covariate strengthened the associ-
ation (HR = 1.003; P ≤ 0.015), suggesting that AAG and MGMT
contribute independently to resistance. In the bivariate model,
the difference in risk of progression between the GBMs with
the lowest and highest AAG activity was approximately 12-fold
(i.e., 1.003820).
Ape1 PROMOTES RESISTANCE TO TMZ
Bacterial and yeast mutants lacking repair activities analogous to
human Ape1 and cells from Ape1 heterozygous mice are hyper-
sensitive to laboratory and clinically utilized methylating agents
(Evans et al., 2000; Abbotts and Madhusudan, 2010). Ape1 con-
tributes to methylator resistance in a variety of human tumor
cells as demonstrated by experiments showing that suppressing
Ape1-mediated Ap endo activity increased drug sensitivity while
increasing activity promoted resistance (Evans et al., 2000; Abbotts
and Madhusudan, 2010). Below, we discuss the evidence that
repair of abasic sites by Ape1 contributes to TMZ resistance in
human GBM cells and tumors.
Ape1 ENZYMATIC ACTIVITIES AND FUNCTION
Ape1 (also Ape1/Ref-1) is a multifunctional protein that is ubiq-
uitously expressed in human cells. Ape1 fosters cell survival by
participating in repair of endogenously and exogenously induced
cytotoxic DNA lesions and by activating transcription factors that
promote resistance to stress (Abbotts and Madhusudan, 2010).
Ape1 also participates in the regulation of calcium-dependent
gene expression and has roles in processing rRNA and mRNA.
At least some of these Ape1-mediated functions are necessary for
survival, as evidenced by the early embryonic lethality of APE1
knockout mice (Izumi et al., 2005). The multi-functionality of
Ape1 is reﬂected in its unusual abundance (>105 copies per cell)
and its distribution in cytoplasm and mitochondria as well as the
nucleus.
Ape1 possesses a strong Ap endo activity that accounts for
more than 95% of the abasic site incision activity observed in
human cells (reviewed in Tell et al., 2009; Abbotts and Mad-
husudan, 2010). In addition to Ap endo activity, Ape1 also has
3′-phosphodiesterase, 3′-phosphatase, and 3′-exonuclease activi-
ties that are critical for repair of abasic sites and SSBs containing
fragmented 3′-deoxyribose or 3′-phosphate induced by the reac-
tion of oxidative free radicals at DNA bases and deoxyribose,
accounting for a role for Ape1 in resistance to ionizing radia-
tion. All of these activities are catalyzed by a common active
site located in the C-terminus of the protein. The N-terminus
of Ape1 is the redox protein Ref-1 that participates in response
to DNA damage-induced stress, cell cycle control and apoptosis
by maintaining critical transcription factors in an active, reduced
state. Ref-1 has also been implicated in regulating the transac-
tivation and proapoptotic functions of p53. Notably, exogenous
oxidative stress, including hypoxia and ionizing radiation, tran-
siently elevate Ape1 protein content and Ap endo activity and
increase alkylating agent resistance in human tumor cell lines (e.g.,
Silber et al., 2002). These properties indicate that Ape1 plays a
critical role in GBM resistance to adjuvant radiation and alky-
lating agents, a conclusion supported by the evidence presented
below.
Ape1 PROMOTES RESISTANCE TO TMZ IN GBM CELLS
In early experiments, Ono et al. (1994) found that suppressing
Ap endo activity in rat glioma cells by using antisense expres-
sion constructs was accompanied by greater sensitivity to the
methylating agent MMS and to the oxidizing agent hydrogen
peroxide. In subsequent work, the same group reported that sen-
sitivity to MMS and hydrogen peroxide was inversely correlated
with Ap endo activity in a panel of human glioma-derived cell
lines (Ono et al., 1995). These experiments, however, provided
no information as to which Ape1 function promoted resistance.
To address this question and to further investigate the role of
Ape1 in alkylator resistance, we used anti-Ape1 ASO to show
that suppressing Ap endo activity in the MGMT-deﬁcient human
GBM line SNB19 increased sensitivity to TMZ (Silber et al., 2002).
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TMZ hypersensitivity was accompanied by elevated abasic site
content, indicating that failure to excise abasic sites contributed,
at least in part, to the potentiation of cell killing. Conversely,
elevatingAp endo activity by exposing cells to minimally cytotoxic
oxidative stress increased TMZ resistance and reduced abasic site
content. Comparable effects on survival were observed for cells
treated with the chloroethylating agent 1,3-bis(2-chloroethyl)-
1- nitrosourea (BCNU, carmustine). In subsequent experiments,
we showed that suppression of Ap endo activity with anti-Ape1
ASO increased killing by the sequence-speciﬁc methylator Me-Lex
in MGMT-proﬁcient, MGMT-deﬁcient, and MGMT- and mis-
match repair-deﬁcient GBM lines (Bobola et al., 2007). Increased
cytotoxicity was accompanied by elevated abasic site content, indi-
cating that lack of Ape1-mediated repair of abasic sites arising from
excision of 3-meA promoted cell killing. Together, these two stud-
ies provide evidence that failure to excise abasic sites derived from
TMZ-induced N-methylpurines contributes to GBM cell killing
regardless of the ability to repair or tolerate O6-meG. A poten-
tial role for Ape1 in promoting resistance to adjuvant therapy in
primary brain tumors in addition to GBMs is supported by our
ﬁndings that suppressing Ape1 expression and Ap endo activity
increases the sensitivity of pediatric ependymoma cells to radia-
tion (Bobola et al., 2011) and medulloblastoma cells to TMZ and
BCNU (Bobola et al., 2005). In the latter case, TMZ sensitivity was
also increased in MGMT- and mismatch-repair deﬁcient medul-
loblastoma cells that are insensitive to the lethality of unrepaired
O6-meG.
Ape1 IN GLIOMA TISSUE AND ASSOCIATION WITH
TREATMENT RESPONSE
Ape1 expression has been the subject of intensive investigation
in a number of human cancers, including primary brain tumors
(Bobola et al., 2004, 2005, 2011). In an initial study of human
adult gliomas (Bobola et al., 2001), our laboratory assayedAp endo
activity in 84 tumors to establish correlates with tumor character-
istics, and in histologically normal brain adjacent to 58 of the
tumors to characterize changes in activity accompanying neuro-
carcinogenesis. Activity in all gliomas ranged ca. 550-fold and
was, on average, 3.5-fold greater in anaplastic gliomas and GBMs
than in low-grade tumors, suggesting that proliferation may be a
determinant of activity. In accord, Ap endo activity was positively
correlated with the fraction of S-phase cells. In the 58 cases of
tumor paired with adjacent normal brain, mean activity was more
than sevenfold higher in tumor than in normal tissue. Increased
tumor activity was observed in 93% of tumor/normal pairs, indi-
cating that elevation of Ap endo activity is characteristic of human
gliomagenesis. The elevation was large in most pairs, being 13-fold
on average and ≥10-fold in 43% of cases. A concomitant increase
in Ape1 protein was observed by Western blotting in the sub-
set of tumor/normal pairs examined. These ﬁndings suggest that
the increase in Ap endo activity that accompanies gliomagenesis
could enhance resistance to adjuvant therapy for GBM and other
gliomas.
Numerous reports have described an inverse association
between immunopositivity forApe1 and clinical course in a variety
of human tumors (Evans et al., 2000; Abbotts and Madhusudan,
2010). To extend these studies to human gliomas and to evaluate
Ap endo activity as a marker of treatment response, we examined
the association of Ap endo activity with PFS following sequential
treatment with radiation and alkylating agents in 30 anaplastic
gliomas and 34 GBMs (Bobola et al., 2004). Cox regression analy-
sis with Ap endo activity entered as a continuous variable revealed
an inverse relationship with a HR for progression following alky-
lator therapy in the anaplastic gliomas increasing by a factor of
1.061 for every 0.01 increase in activity (P = 0.013). In contrast,
we observed no association between activity and PFS in the GBMs,
a result we attributed, in part, to the narrow range of PFS displayed
by the tumors.
More recently, we have analyzed the association between Ap
endo activity and PFS following treatment with alkylating agents
in 80 de novo GBMs that differed in Ap endo activity by ∼225-
fold (Bobola and Silber, in preparation). Sixty-four tumors
were treated with radiation followed by alkylating agent-based
chemotherapy and 16 were treated with concurrent TMZ-RT. A
dichotomous Cox regression model revealed a twofold greater risk
of progression (HR = 2.07; P ≤ 0.003) for tumors with greater
than median Ap endo activity. Analyzing Ap endo as a continuous
variable revealed that the risk of progression increased by a factor
of 1.050 for every 0.01 unit increase in activity (P ≤ 0.022). In
this group of GBMs, the difference in risk of progression between
the tumor with the highest and lowest Ap endo activity was 3.3-
fold. Analyses of 65 anaplastic gliomas that differed in Ap endo
activity by 760-fold revealed a 2.1-fold greater risk for progression
associated with activities greater than the median (P ≤ 0.022),
and a 1.035 increase in risk for each 0.01 unit increase in activity
(P ≤ 0.005) indicative of an 8.7-fold difference in risk between
the tumors with the lowest and highest activities. These ﬁnd-
ings strongly indicate that Ap endo activity promotes resistance
to alkylator agent therapy in GBMs and anaplastic gliomas. They
also suggest that Ap endo activity may have utility as a marker
of treatment response and is a potential target for anti-resistance
therapies.
CIRCUMVENTING REPAIR OF ABASIC SITES TO REDUCE
TMZ RESISTANCE
The association of DNA repair with clinical response to ther-
apeutic DNA damaging agents has provided strong impetus to
develop inhibitors of repair to improve treatment outcome. Char-
acterization of inhibitors of MGMT (e.g., O6-benzylguanine,
lomeguatrib) and of PARP1 (e.g., olaparib; ABT-888) to circum-
vent resistance to TMZ are paradigms for this strategy (Mrugala
and Chamberlain, 2008; Leonetti et al., 2012).
The role of Ape1 in promoting resistance to adjuvant therapy
in GBM and other gliomas has stimulated interest in developing
small molecule inhibitors targeting Ap endo activity (Wilson and
Simeonov, 2010). Lucanthone, a DNA intercalator used to treat
schistosomiasis (Bases and Mendez, 1997), was the ﬁrst potential
inhibitor identiﬁed. Lucanthone has been reported to inhibit inci-
sion at abasic sites by Ape1 in vitro and increase abasic site content
inHeLa cells (Mendez et al., 2002), and to increase TMZ sensitivity
in human breast cancer cells (Luo and Kelley, 2004) and human
GBM cells (Silber and Bobola, unpublished observations). The
mechanism of action was initially believed to involve drug interca-
lation that obscures abasic sites, butmore recent evidence indicates
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that lucanthone acts, at least in part, by binding to the active site
of Ape1 (Naidu et al., 2011). Lucanthone has also been shown
to sensitize brain metastases to radiation (Del Rowe et al., 1999).
On the basis of this sensitization, together with demonstrated
safety and ability to cross the blood brain barrier (Del Rowe et al.,
1999), lucanthone is currently in phase II trial (NCT01587144)
to evaluate safety and efﬁcacy in GBMs treated with concurrent
TMZ-RT.
Ongoing investigation using high-throughput screening cou-
pled with molecular modeling of active site binding has iden-
tiﬁed a large number of potential small molecule inhibitors of
Ape1-catalyzed Ap endo activity (Bapat et al., 2010; Wilson and
Simeonov, 2010; Mohammed et al., 2011; Rai et al., 2012). While
all of these compounds inhibit Ap endo activity in vitro, only
a limited number have been shown to sensitize cells to TMZ.
Madhusudan et al. (2005) identiﬁed inhibitors from a library of
over 2.5 million compounds (e.g., 7-nitro-indole-2-carboxylic
acid) that sensitized ﬁbrosarcoma and GBM cells to MMS and
TMZ (Madhusudan et al., 2005; Mohammed et al., 2011). Bapat
et al. (2010) identiﬁed four potential inhibitors, including one
(AR03) that elicited hypersensitivity to MMS and TMZ in the
malignant glioma line SF767. Both groups reported that methy-
lator hypersensitivity was accompanied by elevated abasic site
content, affording evidence of inhibition of Ap endo activity
in vivo. More recently, a series of Ape1 Ap endo inhibitors
based on 2-methyl-4-amino-6,7-dioxolo-quinoline was shown
to increase sensitivity to the methylator Me-Lex and to con-
comitantly increase abasic site content in the human GBM
line T98G (Srinivasan et al., 2012). Also, Rai et al. (2012) have
described synthesis and characterization of the inhibitor, N-(3-
(benzo[d]thiazol-2-yl)-6-isopropyl-4,5,6,7 tetrahydrothieno[2,3-
c)pyridin-2yl)acetamide that sensitized HeLa cells to MMS and
TMZ.Of note, this lipophilic compound readily crossed the blood-
brain barrier of mice, satisfying one requirement for efﬁcacy in
treating human gliomas.
To our knowledge there are no small molecule inhibitors of
AAG in development. However, the advent of site-speciﬁc methy-
lators that produce 3-meA at ∼ninefold higher yields than TMZ
(Fronza and Gold, 2004) suggest that it may be possible to induce
numbers of adducts that are sufﬁcient to overwhelm tumor cell
repair capacity.
CONCLUSIONS AND FUTURE CONSIDERATIONS
The demonstration that MGMT promoter methylation status is
associated with GBM response to TMZ-based therapies high-
lights the potential importance of DNA repair in determining
clinical course (Silber et al., 2012). However, methylation status
does not accurately predict treatment response in the majority of
GBM, suggesting that MGMT is not the sole, or even the pre-
dominant, determinant of therapeutic response. As set out in this
review, there is now increasing evidence that AAG and Ape1 also
promote resistance in GBMs treated with TMZ and other alkyla-
tors, supporting themultifactorial nature of DNA repair-mediated
treatment failure in GBMs. The clinical relevance of repair of 3-
meA and abasic sites is illustrated in Table 2 which documents our
ﬁnding that the association of tumor AAG and Ap endo activities
with alkylating agent response is comparable to that of MGMT.
Table 2 | Association of AAG,Ape1, and MGMT activity with GBM
resistance to radiation and alkylating agents: one laboratory’s
experiencea.
Repair activityb Nc HR B =
AAG 60 1.64 0.082
Ape1 80 2.07 0.003
MGMT 87 1.90 0.006
aRisk for progression following radiation and alkylator therapy was determined by
Cox proportional hazards regression in dichotomous models with median activity
as the cut point. See text for details.
bActivities in GBMs were measured by biochemical assay.
cTumors assayed for AAG and Ape1 were from the sample of 87 assayed for
MGMT.
The goal now is to translate this knowledge into more effective
treatments for GBM.
The emerging data reviewed here suggest that that AAG and
Ape1 may have utility as markers of clinical response to TMZ-
based adjuvant therapy. Inclusion of AAG and/or Ape1 together
with MGMT expression in multivariate models may allow more
accurate prediction of clinical response and further the goal of
individualizing treatment for GBM, an expectation supported by
the stratiﬁcation of survival based on AAG immunopositivity
in both MGMT promoter methylated and unmethylated GBMs
(Agnihotri et al., 2012). Realizing this goal will require develop-
ment of clinically tractable assays for these proteins. Assay of AAG
and Ape1-mediated Ap endo activity is not currently practical for
routine clinical laboratory use. IHC and surrogate measures of
gene expression, such as promoter methylation status, have the
advantage of using ﬁxed tissue as starting material. In the case of
AAG, both of these approaches may be efﬁcacious, as evidenced
by the stratiﬁcation of survival based on AAG immunopositiv-
ity mentioned above, and initial evidence that AAG expression is
inversely associated with methylation of promoter CpG islands
(Agnihotri et al., 2012). Ape1 expression is particularly attrac-
tive as a marker of GBM clinical outcome because of its multiple
DNA repair and non-repair functions that promote resistance to
radiation as well as alkylating agents (Abbotts and Madhusudan,
2010). Numerous studies have associated Ape1 immunopositivity
with clinical response in a variety of human cancers, suggest-
ing that this measure may prove useful in GBM and other adult
gliomas.
AAGandApe1 are also attractive targets for anti-resistance ther-
apies to enhance the effectiveness of TMZ and other alkylators. As
discussed, suppressingAAG orApe1 expression is accompanied by
greater alkylator sensitivity in human GBM cells regardless of their
ability to repair or tolerate cytotoxic O6-meG. The development
of small molecule inhibitors of theAp endo activity of Ape1 and of
sequence-speciﬁc alkylators that produce 3-meA as the sole cyto-
toxic lesion are active areas of investigation. The promising recent
results suggesting the potential of these strategies to improve clin-
ical outcome must be tempered by the difﬁculty in translating
preclinical ﬁndings withGBMcells into effective human therapies.
Clinical utilization requires circumventing numerous pharma-
cological limitations, including stability, solubility, excretion,
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and ability to penetrate physiological barriers. In addition, sys-
temic administration of inhibitor molecules increases the risk of
producing unacceptable off-target toxicity that leads to efﬁcacy-
compromising alkylator dose reductions. Circumventing these
problemswill require pharmacologically compatible delivery vehi-
cles that sequester inhibitor during transit, penetrate the blood-
brain barrier and speciﬁcally target tumor cells. Prototypes of such
agents have been described, but this area of research is still in its
infancy.
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